

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

IMBACH ET AL.

APPLICATION NO:

FILED: August 10, 2001

FOR: 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS
MEDICAMENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced patent application, please amend the application as follows:

In the Specification:

Please insert the following after the title, page 1,

--This application is a continuation of PCT Patent Application No. PCT/EP00/01271, filed February 16, 2000, which in its entirety is herein incorporated by reference.--

In the Claims:

Please cancel claims 13, 15 and 16.

Please amend claims 12, 14, 17 and 18 as follows:

12. (Amended) A compound of the formula I according to claim 1 or a pharmaceutically acceptable salt of such a compound for use in a method for therapeutic treatment of the human or animal body.

14. (Amended) A pharmaceutical composition for treatment of tumours in warm-blooded animals, including humans, comprising an antitumourally effective dose of a compound of the formula I according to claim 1 or a pharmaceutically acceptable salt of such a compound together with a pharmaceutical carrier.

17. (Amended) A method for treatment of warm-blooded animals, including humans, in which an antitumourally effective dose of a compound of the formula I according to claim 1 or of a pharmaceutically acceptable salt of such a compound is administered to such a warm-blooded animal suffering from a tumour disease.

18. (Amended) A method for treatment of warm-blooded animals, including humans, in which a dose, which is effective against osteoporosis, of a compound of the formula I according to claim 1 or of a pharmaceutically acceptable salt of such a compound is administered to such a warm-blooded animal suffering from osteoporosis.

REMARKS


Claims 12-18 have been amended to eliminate multiple dependency. Favorable consideration of this application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "VERSIONS WITH MARKINGS TO SHOW CHANGES MADE."

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6922

Date: August 10, 2001

Respectfully submitted,


George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 12, 14, 17 and 18 have been amended as follows:

12. A compound of the formula I according to ~~any one of claims 1-11~~ claim 1 or a pharmaceutically acceptable salt of such a compound for use in a method for therapeutic treatment of the human or animal body.

14. A pharmaceutical composition for treatment of tumours in warm-blooded animals, including humans, comprising an antitumourally effective dose of a compound of the formula I according to ~~any one of claims 1-11~~ claim 1 or a pharmaceutically acceptable salt of such a compound together with a pharmaceutical carrier.

17. A method for treatment of warm-blooded animals, including humans, in which an antitumourally effective dose of a compound of the formula I according to ~~any one of claims 1-11~~ claim 1 or of a pharmaceutically acceptable salt of such a compound is administered to such a warm-blooded animal suffering from a tumour disease.

18. A method for treatment of warm-blooded animals, including humans, in which a dose, which is effective against osteoporosis, of a compound of the formula I according to ~~any one of claims 1-11~~ claim 1 or of a pharmaceutically acceptable salt of such a compound is administered to such a warm-blooded animal suffering from osteoporosis.